Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis
- PMID: 31427752
- DOI: 10.1038/s41380-019-0474-5
Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis
Abstract
Predicting antidepressant treatment response has been a clinical challenge for major depressive disorder (MDD). The inflammation hypothesis of depression suggests that cytokines play a key role in the pathophysiology of MDD and alterations in peripheral cytokine levels are associated with antidepressant treatment outcome. Present meta-analysis aimed to examine the association between baseline peripheral cytokine levels and the response to antidepressant treatment and to evaluate whether changes of cytokine levels were associated with the response to antidepressant treatment in patients with MDD. Human-based studies published in any language in peer-reviewed journals were systematically searched from the PubMed, Embase and Web of Science databases, from inception up to October 2018. The search terms included cytokine, depressive disorder and antidepressant and their synonyms. Case-control or case-case studies reporting on levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, CRP, TNF-α, IFN-γ, GM-CSF, MIP-1α, and Eotaxin-1 in patients with MDD based on validated depression scales both before and after antidepressant treatment were included. Of 7408 identified records, 44 studies met inclusion. Standardized mean differences in each cytokine were evaluated, and random-effects meta-analyses were performed. MDD patients who responded to antidepressant treatment had lower baseline IL-8 levels than the nonresponders (Hedge's g = -0.28; 95%CI, -0.43 to -0.13; P = 0.0003; FDR = 0.004). Antidepressant treatment significantly decreased levels of TNF-α (Hedge's g = 0.60; 95%CI, 0.26-0.94; P = 0.0006; FDR = 0.004) only in responders, and responders showed significantly more decreased TNF-α levels compared with nonresponders (P = 0.046). These findings suggested that alterations in peripheral cytokine levels were associated with antidepressant treatment outcomes in MDD. Further investigations are warranted to elucidate sources of heterogeneity and examine the potentiality of using inflammatory cytokines as novel predictive markers for the pharmacological treatment of MDD.
Similar articles
-
Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis.Mol Neurobiol. 2018 May;55(5):4195-4206. doi: 10.1007/s12035-017-0632-1. Epub 2017 Jun 13. Mol Neurobiol. 2018. PMID: 28612257
-
Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):217-226. doi: 10.1016/j.pnpbp.2017.04.026. Epub 2017 Apr 23. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 28445690
-
Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder.Int Immunopharmacol. 2023 May;118:110108. doi: 10.1016/j.intimp.2023.110108. Epub 2023 Mar 31. Int Immunopharmacol. 2023. PMID: 37004349
-
Painful physical symptoms and antidepressant treatment outcome in depression: a systematic review and meta-analysis.Mol Psychiatry. 2024 Aug;29(8):2560-2567. doi: 10.1038/s41380-024-02496-7. Epub 2024 Mar 13. Mol Psychiatry. 2024. PMID: 38480874
-
Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis.Eur Neuropsychopharmacol. 2020 Dec;41:40-51. doi: 10.1016/j.euroneuro.2020.09.633. Epub 2020 Sep 24. Eur Neuropsychopharmacol. 2020. PMID: 32980240
Cited by
-
Constipation preceding depression: a population-based cohort study.EClinicalMedicine. 2024 Jan 16;67:102371. doi: 10.1016/j.eclinm.2023.102371. eCollection 2024 Jan. EClinicalMedicine. 2024. PMID: 38264501 Free PMC article.
-
Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation.Psychoneuroendocrinology. 2024 Nov;169:107145. doi: 10.1016/j.psyneuen.2024.107145. Epub 2024 Jul 24. Psychoneuroendocrinology. 2024. PMID: 39096755
-
Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness.Cells. 2023 Feb 23;12(5):710. doi: 10.3390/cells12050710. Cells. 2023. PMID: 36899845 Free PMC article. Review.
-
Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study.Front Psychiatry. 2021 Dec 24;12:801738. doi: 10.3389/fpsyt.2021.801738. eCollection 2021. Front Psychiatry. 2021. PMID: 35002816 Free PMC article.
-
Efficacy of a Functional Therapy Program for Depression and C-Reactive Protein: A Pilot Study.Clin Neuropsychiatry. 2021 Aug;18(4):188-195. doi: 10.36131/cnfioritieditore20210402. Clin Neuropsychiatry. 2021. PMID: 34909034 Free PMC article.
References
-
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40. - DOI
-
- Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry. 1995;19:11–38. - DOI
-
- Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous